Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism Research, West China Hospital, Sichuan University, Chengdu, China; Department of General Medicine, Chongqing University Central Hospital, Chongqing Emergency Medical Center, Chongqing Key Laboratory of Emergency Medicine, Chongqing, China.
Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism Research, West China Hospital, Sichuan University, Chengdu, China.
Acta Biomater. 2024 Mar 15;177:377-387. doi: 10.1016/j.actbio.2024.01.036. Epub 2024 Feb 1.
Sepsis, defined as a life-threatening organ dysfunction, is associated with increased mortality in individuals with diabetes mellitus. In sepsis under diabetic conditions (SUDC), the superimposed inflammatory response and excessive production of reactive oxygen species (ROS) can cause severe damage to the kidney and liver, making it challenging to effectively repair multi-organ injury. In this study, we report the development of a DNA-based bifunctional nanomedicine, termed IL10-rDON, generated by assembling interleukin 10 (IL10) with rectangular DNA origami nanostructures (rDON) to address multi-organ dysfunction in SUDC. IL10-rDON was shown to predominantly accumulate in the kidney and liver of diabetic mice in vivo and effectively alleviate inflammatory responses through its anti-inflammatory IL10 component. In addition, the consumption of rDON itself significantly reduced excessive ROS in the liver and kidney. Serum and histological examinations further confirmed that IL10-rDON treatment could effectively improve liver and kidney function, as well as the survival of mice with SUDC. This study demonstrates an attractive antioxidant and anti-inflammatory nanomedicine for addressing acute liver and renal failure. The integration of rDON with therapeutic agents using DNA nanotechnology is a promising strategy for generating multifunctional nanomedicine to treat multi-organ dysfunction and other complicated diseases. STATEMENT OF SIGNIFICANCE: Sepsis under diabetic conditions (SUDC) leads to high mortality due to multiple organ failure such as acute liver and kidney injury. The anti-inflammatory cytokine interleukin 10 (IL10) holds great potential to treat SUDC, while disadvantages of IL-10 such as short half-life, non-specific distribution and lack of antioxidant activities limit its wide clinical applications. In this study, we developed a DNA-based, bifunctional nanomedicine (IL10-rDON) by assembling IL10 with rectangular DNA origami nanostructures (rDON). We found that IL10-rDON preferentially accumulated and sufficiently attenuated the increased levels of ROS and inflammation in the kidney and liver injury sites, and eventually improved the survival rate of mice with SUDC. Our finding provides new insights into the application of DNA-based nanomedicine in treating multi-organ failure.
败血症是一种危及生命的器官功能障碍,与糖尿病患者的死亡率增加有关。在糖尿病合并败血症(SUDC)中,叠加的炎症反应和活性氧(ROS)的过度产生会对肾脏和肝脏造成严重损害,使得有效修复多器官损伤变得具有挑战性。在这项研究中,我们报告了一种基于 DNA 的双功能纳米药物的开发,称为 IL10-rDON,它是通过将白细胞介素 10(IL10)与矩形 DNA 折纸纳米结构(rDON)组装而成的,用于解决 SUDC 中的多器官功能障碍。研究表明,IL10-rDON 主要在糖尿病小鼠的肾脏和肝脏中积累,并通过其抗炎的 IL10 成分有效缓解炎症反应。此外,rDON 本身的消耗显著减少了肝脏和肾脏中的过量 ROS。血清和组织学检查进一步证实,IL10-rDON 治疗可有效改善 SUDC 小鼠的肝肾功能和存活率。这项研究展示了一种有吸引力的抗氧化和抗炎纳米药物,可用于治疗急性肝肾功能衰竭。使用 DNA 纳米技术将 rDON 与治疗剂整合在一起是一种很有前途的策略,可以生成多功能纳米药物来治疗多器官功能障碍和其他复杂疾病。
糖尿病合并败血症(SUDC)会导致急性肝肾功能衰竭等多器官衰竭,死亡率很高。抗炎细胞因子白细胞介素 10(IL10)具有治疗 SUDC 的巨大潜力,但其半衰期短、非特异性分布和缺乏抗氧化活性等缺点限制了其广泛的临床应用。在这项研究中,我们通过将 IL10 与矩形 DNA 折纸纳米结构(rDON)组装,开发了一种基于 DNA 的双功能纳米药物(IL10-rDON)。我们发现,IL10-rDON 优先在肾脏和肝脏损伤部位聚集,并充分减弱了 ROS 和炎症的增加水平,最终提高了 SUDC 小鼠的存活率。我们的发现为基于 DNA 的纳米药物在治疗多器官衰竭中的应用提供了新的见解。